Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | XBP1 | P17861 | 1/20 | 0.49 |
| ▸ | ACACB | O00763 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1628642 | 0.86 | LMNA (0.62) | MAPTMEN1KMT2AALOX12POLB | |
| SCHEMBL123415 | 0.84 | MAPT (0.55) | MAPTMEN1KMT2AALOX12POLB | |
| SCHEMBL8047274 | 0.84 | ACACB (0.52) | MAPTMEN1KMT2AALOX12POLB | |
| SCHEMBL15114294 | 0.83 | LMNA (0.57) | MAPTMEN1KMT2AALOX12POLB | |
| SCHEMBL16902890 | 0.82 | PPARG (0.41) | MAPTMEN1KMT2AALOX12POLB | |
| SCHEMBL10916977 | 0.81 | LTA4H (0.40) | MAPTMEN1KMT2AALOX12LMNA | |
| SCHEMBL7477540 | 0.81 | NPC1 (0.54) | MAPTMEN1KMT2AALOX12POLB | |
| SCHEMBL4527180 | 0.81 | MAPT (0.50) | MAPTMEN1KMT2AALOX12POLB | |
| SCHEMBL13155583 | 0.81 | ACACB (0.53) | MAPTMEN1KMT2AALOX12POLB | |
| SCHEMBL18608209 | 0.80 | ACACB (0.52) | MAPTMEN1KMT2AALOX12POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107011137-B | Synthetic method of pimavanserin intermediate | 杭州科耀医药科技有限公司 | 2020-09-11 | — | — | CN | claimed |
| CN-111517966-A | Method for synthesizing p-isobutoxybenzylamine | 杭州益至生物科技有限公司 | 2020-08-11 | — | — | CN | claimed |
| US-20240299559-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-12 | — | — | US | disclosed |
| US-11840515-B2 | Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c | ACADIA PHARMACEUTICALS INC. (US) | 2023-12-12 | — | — | US | disclosed |
| WO-2023069700-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-11440884-B2 | Compounds, salts thereof and methods for treatment of diseases | ACADIA PHARMACEUTICALS INC. (US) | 2022-09-13 | — | — | US | disclosed |
| US-20220024871-A1 | METHODS FOR PREPARING N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND POLYMORPHIC FORM C | ACADIA PHARMACEUTICALS INC. | 2022-01-27 | — | — | US | disclosed |
| EP-3325444-B1 | METHODS FOR PREPARING N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND POLYMORPHIC FORM C | ACADIA PHARM INC (US) | 2021-07-07 | — | — | EP | disclosed |
| CN-107848972-B | Process for the preparation of N- (4-fluorobenzyl) -N- (1-methylpiperidin-4-yl) -N' - (4- (2-methylpropyloxy) phenylmethyl) urea and its tartrate salt and polymorph C | 阿卡蒂亚药品公司 | 2021-06-18 | — | — | CN | disclosed |
| US-20210122713-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARMACEUTICALS INC. (US) | 2021-04-29 | — | — | US | disclosed |
| US-20210122713-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARMACEUTICALS INC. (US) | 2021-04-29 | — | — | US | disclosed |
| EP-3325444-A1 | METHODS FOR PREPARING N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND POLYMORPHIC FORM C | Acadia Pharmaceuticals Inc. (US) | 2018-05-30 | — | — | EP | disclosed |
| CN-107848972-A | For preparing N (4 luorobenzyl) N (base of 1 methyl piperidine 4) N ' (4 (2 methyl propoxyl group) phenyl methyl) ureas and its tartrate and polymorphic C method | 阿卡蒂亚药品公司 | 2018-03-27 | — | — | CN | disclosed |
| US-20180037549-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PIMAVANSERIN | TAPI CROATIA INDUSTRIES LTD (HR) | 2018-02-08 | — | — | US | disclosed |
| US-20180037549-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PIMAVANSERIN | TAPI CROATIA INDUSTRIES LTD (HR) | 2018-02-08 | — | — | US | disclosed |
| US-20180037549-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PIMAVANSERIN | TAPI CROATIA INDUSTRIES LTD (HR) | 2018-02-08 | — | — | US | disclosed |
| EP-3271018-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PIMAVANSERIN | Pliva Hrvatska D.O.O. (HR) | 2018-01-24 | — | — | EP | disclosed |
| WO-2017015272-A1 | METHODS FOR PREPARING N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND POLYMORPHIC FORM C | ACADIA PHARMACEUTICALS INC. (US) | 2017-01-26 | — | — | WO | disclosed |
| WO-2017015272-A1 | METHODS FOR PREPARING N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND POLYMORPHIC FORM C | ACADIA PHARMACEUTICALS INC. (US) | 2017-01-26 | — | — | WO | disclosed |
| US-6106999-A | SENSITIVITY TO GENERAL-PURPOSE VISIBLE LIGHT LASER, SO THAT HIGH-SPEED SCANNING EXPOSURE IS POSSIBLE BY LASER, AND EXTREMELY FINE HIGH RESOLUTION CAN BE OBTAINED; CAN BE USED FOR COATING OR PRINTING UNDER SAFELIGHT IRRADIATING CONDITIONS | MITSUI CHEMICALS (JP) | 2000-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840515-B2 | Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c | NR3C2, NR2C2, CYP4A22 | MAPT 4837/4885MEN1 4247/4885KMT2A 797/4885 |
| US-20220024871-A1 | METHODS FOR PREPARING N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND POLYMORPHIC FORM C | NR3C2, NR2C2, CYP4A22 | MAPT 4837/4885MEN1 4241/4885KMT2A 795/4885 |
| US-11440884-B2 | Compounds, salts thereof and methods for treatment of diseases | SLC10A1, VHL, CYP11B2 | MAPT 1266/4885MEN1 264/4885KMT2A 3216/4885 |
| US-20210122713-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | SLC10A1, VHL, CYP11B2 | MAPT 1266/4885MEN1 264/4885KMT2A 3216/4885 |
| US-20240299559-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | CDK2, SKP2, CDK1 | MAPT 3248/4885MEN1 2754/4885KMT2A 2021/4885 |
| US-20180037549-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PIMAVANSERIN | PIM1, PIM3, PIM2 | MAPT 2923/4885MEN1 3691/4885KMT2A 1480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.